Clinical trials: Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed/Refractory B-cell Lymphoma
RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
This single-arm, open-label pilot study will assess the safety and efficacy of RN1701, a bispecific CD19/CD20-targeted allogeneic CAR-T-cell product, in patients with relapsed or refractory B-cell lymphoma.
- Trial name
- NCT07563543
- Testing
- RN1701 injection
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Lymphoma, B-Cell
CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma
The is a prospective, open-label, dose-climbing clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 15 subjects with r/r CD30+ lymphoma。
- Trial name
- NCT06850285
- Testing
- chimeric antigen receptor gene modified T cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanxi Bethune Hospital
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
- Trial name
- VITALIZE (NCT04920617)
- Testing
- DPX-Survivac, Pembrolizumab, CPA
- Where
- 50 sites in United States, Australia and 8 more
- Volunteers
- 102 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
B-cell Acute Lymphoblastic Leukemia
SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
This study aims to evaluate the safety and pharmacokinetic profile of SNC116 in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia
- Trial name
- NCT07830238
- Testing
- SNC116
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma
Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
The major aim of this research is to assess the feasibility, safety and effectiveness of CD19 CAR-T Cell Therapy for Relapsed/ Refractory Acute Lymphoblastic Leukemia/ B cell Lymphoma patients who have applied it.
- Trial name
- NCT03281551
- Testing
- PZ01 CAR-T cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Pinze Lifetechnology Co. Ltd.
B-cell Acute Lymphoblastic Leukemia, Lymphoblastic B-Cell Lymphoma
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
The purpose of this study is to estimate the safety and the efficacy of CAR- T cells immunotherapy for children/young adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma.
- Trial name
- NCT05333302
- Testing
- CD19 CAR-T-cells, Tocilizumab
- Where
- Belarus
- Volunteers
- 10 people
- Sponsor
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
Diffuse Large B Cell Lymphoma
An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection
This is a single-arm, open-label, dose escalation, phase I study, aiming to evaluate the safety and efficacy of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific Chimeric Antigen Receptor (CAR) T-cells in patient with…
- Trial name
- NCT04486872
- Testing
- Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This is a modular study of AZD2014 in combination with novel anti-cancer agents in patients with different subtypes of relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).
- Trial name
- INHIBITOR (NCT02780830)
- Testing
- AZD2014, Ibrutinib
- Sponsor
- AstraZeneca
Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)
The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to evaluate whether tafasitamab and parsaclisib can be safely combined at the recommended Phase 2 dose (RP2D) and dosing regimen that was…
- Trial name
- topMIND (NCT04809467)
- Testing
- tafasitamab, parsaclisib
- Where
- 50 sites in United States, Austria and 5 more
- Volunteers
- 54 people
- Sponsor
- Incyte Corporation
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia
Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma
- Trial name
- NCT00017472
- Testing
- apolizumab, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
This phase II trial studies how well low-intensity chemotherapy and blinatumomab work in treating patients with Philadelphia chromosome negative acute lymphoblastic leukemia that has come back or does not respond to treatment.
- Conditions
- Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
- Trial name
- NCT03518112
- Testing
- Blinatumomab, Cyclophosphamide, Cytarabine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphoma
Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ixabepilone in treating patients who have relapsed or…
- Trial name
- NCT00052572
- Testing
- ixabepilone
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Childhood Langerhans Cell Histiocytosis, Fanconi Anemia
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Childhood Langerhans Cell Histiocytosis, Fanconi Anemia, Leukemia, Lymphoma
- Trial name
- NCT00084695
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Milton S. Hershey Medical Center
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
This randomized phase II trial studies how well giving tacrolimus and mycophenolate mofetil (MMF) with or without sirolimus works in preventing acute graft-versus-host disease (GVHD) in patients undergoing donor stem cell…
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Refractory Chronic Lymphocytic Leukemia, Refractory Plasma Cell Myeloma
- Trial name
- NCT00105001
- Testing
- Fludarabine Phosphate, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 210 people
- Sponsor
- Fred Hutchinson Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
This phase I trial is studying the side effects, best way to give, and best dose of Akt inhibitor MK2206 (MK2206) in treating patients with recurrent or refractory solid tumors or leukemia.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia
- Trial name
- NCT01231919
- Testing
- Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- 25 sites in United States, Canada
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed/Refractory Large B-cell Lymphoma
A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
This study is a single-arm, multicenter, open-label clinical study evaluating the efficacy and safety of axicabtagene ciloleucel injection manufactured by an automated cell preparation process in adult subjects with relapsed or…
- Trial name
- NCT07606937
- Testing
- FKC876 injection
- Where
- 6 sites in China
- Volunteers
- 12 people
- Sponsor
- Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Cancer
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Antivirals such as valacyclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valacyclovir is effective in preventing cytomegalovirus in patients undergoing stem cell…
- Trial name
- NCT00045292
- Testing
- acyclovir, acyclovir sodium, valacyclovir
- Where
- 6 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
This phase II trial studies the effect of polatuzumab vedotin, venetoclax, and rituximab and hyaluronidase human in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to treatment…
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma
- Trial name
- NCT04659044
- Testing
- Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- Academic and Community Cancer Research United
Chronic Myeloproliferative Disorders, Leukemia
Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer
Phase I trial to study the effectiveness of combining interleukin-12 and interferon alfa in treating patients who have residual, recurrent, or metastatic malignant melanoma or other advanced cancer that has not responded to…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003451
- Testing
- recombinant interferon alfa, recombinant interleukin-12
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B-cell Lymphoma
Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
- Trial name
- NCT00968331
- Testing
- Lenalidomide plus Rituximab
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- University of Bologna
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.